Predominance of Candida Glabrata among Non-albicans Candida Species in a 16-Year Study of Candidemia at a Tertiary Care Center in Lebanon

Aline El Zakhem 1, Rachid Istambouli 1, Maria Alkozah 1, Amal Gharamti 1, Mohamad Ali Tfaily 1, Jean-Francois Jabbour 1, George F. Araj 2, Hani Tamim 1 and Souha S. Kanj 1,*

1 Department of Internal Medicine, American University of Beirut Medical Center, Beirut 1107 2020, Lebanon; az51@aub.edu.lb (A.E.Z.); ri51@aub.edu.lb (R.I.); Maria.Alkozah@hitchcock.org (M.A.); ae107@aub.edu.lb (A.G.); mht19@mail.aub.edu.lb (M.A.T.); jfjabbour@stgeorgehospital.org (J.-F.J.); htamim@aub.edu.lb (H.T.)

2 Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut 1107 2020, Lebanon; garaj@aub.edu.lb

* Correspondence: sk11@aub.edu.lb

Abstract: Background: Candidemia is associated with a high mortality rate, and its incidence is increasing worldwide with a rise in non-albicans candidemia (NAC). Epidemiologic data from Arab countries are scarce and there are no data from Lebanon; Methods: This is a single-center retrospective chart review of patients with candidemia in a tertiary care center in Lebanon from 2004 to 2019. We extracted data on patient characteristics, isolated Candida species antifungal susceptibility, management and outcomes; Results: We included 170 cases of candidemia. NAC was more common than albicans candidemia (64.7% vs. 35.3%). C. glabrata was the most common non-albicans species (37 isolates) followed by C. tropicalis (14). Recent use of antifungals was a risk factor for NAC (OR = 2.8, p = 0.01), while the presence of a central venous catheter was protective (OR = 0.41, p = 0.02). Fluconazole resistance was 12.5% in C. albicans and 21.5% in non-albicans spp. Mortality at 30 days was 55.5%, with no difference between NAC and albicans candidemia. It was higher in older and critically ill patients but lower in patients whose central venous catheter was removed after detecting fungemia; Conclusions: Candidemia is associated with high mortality in Lebanon, with a predominance of NAC and high prevalence of C. glabrata.

Keywords: invasive candidiasis; candidemia; non-albicans Candida; Candida glabrata; antifungal susceptibility; Lebanon; Arab world

1. Introduction

Candidemia is the most common form of invasive candidiasis, and is known to be the fourth to seventh most common bloodstream infection [1]. It is often associated with a high mortality rate of approximately 40–60% and a significant economic burden [2–5]. Due to the growing number of immunocompromised patients and critically ill patients, as well as the increasing use of invasive devices and antibiotics, the incidence of candidemia has been increasing around the world [2,6]. Particularly, there has been a rise in the incidence of non-albicans candidemia (NAC) [7].

Data on candidemia from Arab countries are limited [8]. In the absence of national surveillance programs, data are largely based on local studies. The crude mortality rate of candidemia in Arab countries is also elevated, and NAC is becoming more predominant as well [8]. In Lebanon, no studies have been previously done to evaluate the epidemiology of invasive candidiasis or candidemia. However, studies on the distribution of Candida spp. isolated from different sites without differentiation between colonization and true infection suggest an increasing incidence of non-albicans Candida and of fluconazole resistance [9,10].
Our aim is to identify the clinical characteristics of patients with candidemia, the isolated *Candida* spp. and their antifungal susceptibility, and the outcome of the infected patients. We also investigated the risk factors for NAC and increased mortality.

2. Results

2.1. Baseline Characteristics

Over the study period, we identified 193 cases of candidemia. We excluded 23 cases due to unavailability of full medical records. Almost half of the patients were female (49.4%) with a mean age of 65.7 (Table 1). Diabetes mellitus was a comorbid condition in 50 patients (29.4%) and 29 (17.1%) were on hemodialysis at infection onset, of which 19 (11.2%) were started on hemodialysis for acute kidney injury that occurred during the current admission.

Table 1. Baseline characteristics of the patients with candidemia, including demographics, comorbid conditions, immunosuppression, and admission characteristics.

| Characteristics                                      | n (%)       |
|------------------------------------------------------|-------------|
| Demographics and Comorbidities                       |             |
| Age (years, mean ± SD)                               | 65.71 ± 17.175 |
| Female                                               | 84 (49.4)  |
| Diabetes mellitus                                    | 50 (29.4)  |
| Hemodialysis                                         | 29 (17.1)  |
| End-stage renal disease                              | 10 (5.9)   |
| Acute kidney injury                                  | 19 (11.2)  |
| Immunosuppression                                    |             |
| Malignancy                                           | 86 (50.6)  |
| Non-hematologic                                      | 62 (36.5)  |
| Hematologic                                          | 20 (11.8)  |
| Both                                                 | 4 (2.4)    |
| Chemotherapy                                         | 38 (22.4)  |
| <1 week from infection                               | 10 (5.9)   |
| Immunotherapy                                        | 3 (1.8)    |
| Hematopoietic stem cell transplant recipient         | 7 (4.1)    |
| Auto-transplant                                       | 3 (1.8)    |
| Allo-transplant                                       | 3 (1.8)    |
| Both                                                 | 1 (0.6)    |
| Neutropenia                                          | 21 (12.4)  |
| 1000–1500/mm³                                        | 3 (1.8)    |
| 500–1000/mm³                                         | 6 (3.5)    |
| <500/mm³                                             | 12 (7.1)   |
| Current steroids                                      | 36 (21.2)  |
| Solid organ transplant recipient                      | 3 (1.8)    |
| Congenital syndromes                                 | 3 (1.8)    |
| Other immunosuppressants                             | 9 (5.3)    |
| Admission Characteristics                            |             |
| Unit                                                  |             |
| Regular ward                                          | 76 (44.7)  |
| Critical care unit                                    | 82 (48.2)  |
| Emergency department                                 | 12 (7.1)   |
| Abdominal surgery within 30 days                     | 45 (26.5)  |
| Antibiotics use within 30 days                       | 161 (94.7) |
| Antifungals use within 30 days                       | 45 (26.5)  |
| Flucconazole                                         | 31 (18.2)  |
| Voriconazole                                         | 2 (1.2)    |
| Lipid formulation of amphotericin B                  | 4 (2.4)    |
| Caspofungin                                          | 8 (4.7)    |
| Anidulafungin                                        | 2 (1.2)    |
| Duration of previous antifungal (days, mean ± SD)    | 13.43 ± 15.66 |
| Mechanical ventilation                               | 83 (48.8)  |
| Parenteral nutrition                                 | 44 (23.9)  |
| Central venous catheter                              | 117 (68.8) |
| Source                                               |             |
| Gastrointestinal translocation                        | 57 (33.5)  |
| CLABSNI                                              | 40 (23.5)  |
| Urinary tract infection                              | 17 (10)    |
| Vertebral abscess                                    | 1 (0.6)    |
| Aortoiliac graft infection                           | 1 (0.6)    |
| Unknown                                              | 54 (31.8)  |

Data are presented as number (percentage) unless otherwise specified. CLABSNI: Central Line-Associated Bloodstream Infection.
At least one immunosuppressive factor was present in 110 patients (64.7%), malignancy being the most common (86 patients, 50.6%), followed by steroid intake (21.2%) and neutropenia (12.4%). A total of 38 patients had received chemotherapy in the month preceding the candidemia episode, of which 10 had received it in the one-week period prior to the infection onset. Other factors contributing to depressed immunity were immunotherapy (3), hematopoietic stem cell transplant (7), solid organ transplant (3), and congenital syndromes (3).

While 82 patients (48.2%) were admitted to a critical care unit at the onset of infection, 76 (44.7%) were on medical or surgical wards, and 12 (7.1%) were in the emergency department. Moreover, 83 patients (48.8%) were on mechanical ventilation, 44 (25.9%) were receiving parenteral nutrition, and 117 (68.8%) had a central venous catheter. Additionally, in the month prior to candidemia, 45 patients (26.5%) had undergone abdominal surgery, 161 (94.7%) had received antibiotics, and 45 (26.5%) had received antifungals.

A source of candidemia could be identified in 116 episodes (68.2%). The most common source was gastrointestinal translocation (33.5%), followed by Central Line Associated Bloodstream Infection (CLABSI) (23.5%) and urinary tract infection (10%). One case was the result of a vertebral abscess and another was caused by an aortoiliac graft infection.

2.2. Isolated Candida spp. and Antifungal Susceptibility

NAC (110 episodes, 64.7%) was more common than C. albicans candidemia (60 episodes, 35.3%) (Table 2). Speciation of non-albicans Candida was performed in 72 of 110 episodes of NAC. Of the speciated non-albicans Candida, C. glabrata was the most common (37), followed by C. tropicalis (14), Pichia kudriavzevii (C. krusei) (5), Kluyveromyces marxianus (C. kefyr) (3), Clavispora lusitaniae (Candida lusitaniae) (2), and Wickerhamomyces anomalus (C. pelliculosa) (1). There were four cases of mixed candidemia. C. albicans and C. glabrata were the two most commonly isolated species in all identified sources.

Table 2. Species distribution of Candida isolates.

| Candida Species               | n   |
|------------------------------|-----|
| Candida albicans             | 60  |
| Candida non-albicans          | 110 |
| C. glabrata                  | 37  |
| C. tropicalis                | 14  |
| C. parapsilosis              | 6   |
| P. kudriavzevii (C. krusei)  | 5   |
| K. marxianus (C. kefyr)      | 3   |
| C. lusitaniae                | 2   |
| W. anomalus (C. pelliculosa) | 1   |
| C. albicans and C. glabrata  | 1   |
| C. albicans and C. tropicalis| 1   |
| C. albicans and C. dubliniensis| 1  |
| C. albicans and C. parapsilosis| 1  |
| unspeciated                  | 38  |
| **Total**                    | 170 |

Results of the univariate analysis of possible NAC risk factors are shown in Table 3. Multivariate analysis (Table 4) showed that patients with a central venous catheter (CVC) were less likely to have NAC (OR = 0.41, \( p = 0.02 \)), while a history of antifungal use within the last 30 days was associated with a higher likelihood of NAC (OR = 2.78, \( p = 0.01 \)).

Antifungal susceptibility testing to fluconazole was performed on 89 isolates (Table 5). From a total of 24 C. albicans isolates tested, 12.5% were resistant to fluconazole. Non-albicans Candida displayed 21.5% resistance to fluconazole, mainly with C. glabrata (10/33) and P. kudriavzevii (C. krusei) (3/5). Resistance rates for voriconazole were 19.0% among tested C. albicans isolates, and 7.1% among tested non-albicans Candida isolates. All tested
isolates were susceptible to caspofungin (14 isolates), and only 1 isolate of C. glabrata was resistant to amphotericin B (Table S1).

### Table 3. Univariate analysis of possible risk factors associated with non-*albicans* candidemia. Data are presented as number (percentage) unless otherwise specified.

| Variable                                     | C. albicans | C. non-albicans | p-Value |
|----------------------------------------------|-------------|-----------------|---------|
| Age (years, mean ± SD)                       | 68.55 ± 15.5| 64.15 ± 17.9    | 0.111   |
| Female                                       | 26 (43.3)   | 58 (52.7)       | 0.242   |
| Year of admission                            |             |                 |         |
| 2004–2009                                    | 10 (16.7)   | 20 (18.2)       | 0.313   |
| 2010–2014                                    | 26 (43.3)   | 35 (31.8)       |         |
| 2015–2019                                    | 24 (40.0)   | 55 (50.0)       |         |
| Unit                                         |             |                 |         |
| Regular ward                                 | 23 (38.3)   | 53 (48.2)       |         |
| Critical care unit                           | 33 (55.0)   | 49 (44.5)       | 0.418   |
| Emergency department                         | 4 (6.7)     | 8 (7.3)         |         |
| Diabetes mellitus                            | 17 (28.3)   | 33 (30.0)       | 0.820   |
| Hemodialysis patient                         | 13 (21.7)   | 16 (14.5)       | 0.238   |
| End-stage renal disease                      | 6 (10.0)    | 4 (3.6)         | 0.169   |
| Acute kidney injury                          | 7 (11.7)    | 12 (10.9)       | 0.881   |
| Solid organ transplant recipient              | 0 (0.0)     | 5 (100)         | 0.553   |
| Stem cell transplant recipient                | 1 (1.7)     | 6 (5.5)         | 0.423   |
| Auto-transplant                              | 1 (100)     | 2 (33.3)        |         |
| Allo-transplant                              | 0 (0.0)     | 3 (50.0)        | 0.459   |
| Both                                         | 0 (0.0)     | 1 (16.7)        |         |
| Neutropenic                                  | 6 (10.0)    | 15 (13.6)       | 0.628   |
| Immunocompromised                            | 38 (63.3)   | 72 (65.5)       | 0.782   |
| Current steroids                              | 14 (23.3)   | 22 (20.0)       | 0.611   |
| Congenital syndromes                         | 2 (3.3)     | 1 (0.9)         | 0.285   |
| Other immunosuppressants                     | 2 (3.3)     | 7 (6.4)         | 0.495   |
| Malignancy                                    | 27 (45.0)   | 59 (53.6)       | 0.282   |
| Non-hematologic                              | 21 (77.8)   | 41 (69.5)       |         |
| Hematologic                                  | 5 (18.5)    | 15 (25.4)       | 0.729   |
| Both                                         | 1 (3.7)     | 3 (5.1)         |         |
| Chemotherapy                                 | 11 (18.5)   | 27 (24.5)       | 0.353   |
| <1 week from infection                       | 3 (27.3)    | 7 (59.9)        | 1.00    |
| Immunotherapy                                | 0 (0.0)     | 3 (2.7)         | 0.553   |
| Abdominal surgery within 30 days             | 16 (26.7)   | 29 (26.4)       | 0.966   |
| Antibiotics within 30 days                   | 55 (91.7)   | 106 (96.4)      | 0.191   |
| Antifungal history                           | 10 (16.7)   | 35 (31.8)       | 0.032 *|
| Fluconazole                                  | 6 (10.0)    | 25 (22.7)       | 0.040 *|
| Voriconazole                                 | 0 (0.0)     | 2 (1.8)         | 0.541   |
| Amphotericin B                               | 1 (1.7)     | 3 (2.7%)        | 1.00    |
| Caspofungin                                  | 3 (5.0)     | 5 (4.5)         | 1.00    |
| Anidulafungin                                | 0 (0.0)     | 2 (1.8)         | 0.541   |
| Duration of previous antifungal (days, mean ± SD) | 16.6 ± 24.8 | 16.7 ± 27.3    | 0.989   |
| Parenteral nutrition                         | 16 (26.7)   | 28 (25.5)       | 0.863   |
| Central venous catheter                      | 47 (78.3)   | 70 (63.6)       | 0.048 *|
| Source                                       |             |                 |         |
| CLABSI                                       | 18 (30.0)   | 22 (20.0)       | 0.142   |
| Gastrointestinal translocation               | 18 (30.0)   | 39 (35.5)       | 0.472   |
| Urinary tract infection                      | 6 (10.0)    | 11 (10.0)       | 1.00    |
| Unknown                                      | 18 (30.0)   | 36 (32.7)       | 0.715   |
| Other                                        | 0 (0.0)     | 2 (1.8)         | 0.528   |

CLABSI: Central Line-Associated Bloodstream Infection. *: p-values < 0.05.

### Table 4. Multivariate regression for predictors of non-*albicans* candidemia.

| Variable                      | OR (95% CI) | p-Value |
|-------------------------------|-------------|---------|
| Central Venous Catheter       | 0.41 (0.19–0.86) | 0.02    |
| Antifungal History            | 2.78 (1.23–6.25) | 0.01    |

Variables included in the model were central venous catheter, history of antifungal use and history of fluconazole use. OR: Odds Ratio.
2.3. Management and Mortality

Data on mortality were available for 164 patients, and the 30-day crude mortality rate was 55.5%. Of those alive, candidemia recurred in 7 patients. Antifungals were administered to 142 patients (Table 6). An echinocandin (caspofungin, anidulafungin or micafungin) was started in 42.3% of cases, whereas fluconazole was started in 30% (dose of 400 mg daily was used in 16.5%). The mean treatment duration was 16.64 days, and 27.6% of patients received antifungals for more than 14 days after the first negative blood culture. Echocardiography was performed in 90 patients (52.9%), 5 of which had pertinent findings (3 had vegetations and 2 had new onset mitral valve regurgitation). Ophthalmic examination was performed on 35 patients (20.6%), 3 of which (8.6%) were found to have fungal endophthalmitis. Of 117 patients with CVC, 80 had the line removed after detection of candidemia (68.4%) and 67 (57.3%) had the catheter tip sent for culture.

Table 5. Antifungal susceptibility of Candida isolates to fluconazole and voriconazole. % resistant: percentage of isolates resistant to antifungal.

| Candida Species | n | Sensitive | Intermediate | Resistant | % Resistant | n | Sensitive | Intermediate | Resistant | % Resistant |
|-----------------|---|-----------|--------------|-----------|-------------|---|-----------|--------------|-----------|-------------|
| C. albicans     | 24| 21        | 0            | 3         | 12.5%       | 21| 17        | 0            | 4         | 19.0%       |
| C. glabrata     | 33| 21        | 2            | 10        | 30.3%       | 28| 23        | 2            | 3         | 10.7%       |
| C. tropicalis   | 14| 13        | 0            | 1         | 7.1%        | 12| 11        | 0            | 1         | 8.3%        |
| C. parapsilosis | 7 | 7         | 0            | 0         | 0.0%        | 5 | 5         | 0            | 0         | 0.0%        |
| P. kudriavzevi  (C. krusei) | 5 | 1         | 1            | 3         | 60.0%       | 5 | 5         | 0            | 0         | 0.0%        |
| K. marxianus    (C. kefyr) | 3 | 3         | 0            | 0         | 0.0%        | 3 | 3         | 0            | 0         | 0.0%        |
| C. lusitaniae   | 2 | 2         | 0            | 0         | 0.0%        | 2 | 2         | 0            | 0         | 0.0%        |
| W. anomalus (C. pelliculosa) | 1 | 1         | 0            | 0         | 0.0%        | 1 | 1         | 0            | 0         | 0.0%        |
| Total           | 89| 69        | 3            | 17        | 19.1%       | 77| 67        | 2            | 8         | 10.4%       |

Table 6. Management of candidemia.

| Management                     | n (%)   |
|--------------------------------|---------|
| Species identified             | 132 (77.6) |
| Echocardiography               | 90 (52.9)  |
| Ophthalmic exam                | 35 (20.6)  |
| Empiric therapy                |          |
| Fluconazole                    | 51 (30.0)  |
| Caspofungin                    | 41 (24.1)  |
| Anidulafungin                  | 18 (10.6)  |
| Micafungin                     | 13 (7.6)   |
| Lipid formulation of amphotericin B | 12 (7.1)  |
| Itraconazole                   | 5 (2.9)    |
| Voriconazole                   | 2 (1.2)    |
| Empiric therapy changed        | 62 (36.5)  |
| Targeted therapy               |          |
| Fluconazole                    | 31 (18.2)  |
| Voriconazole                   | 6 (3.5)    |
| Caspofungin                    | 10 (5.9)   |
| Anidulafungin                  | 3 (1.8)    |
| Micafungin                     | 3 (1.8)    |
| Lipid formulation of amphotericin B | 8 (4.7)  |
| Other                          | 1 (0.6)    |
| Antifungal duration (days, mean ± SD) | 16.64 ± 26.334 |
| Antifungal at least 14 days after first negative culture | 47 (27.6)  |
| Central venous catheter removed| 80 (47.1)  |
| Tip sent for culture           | 67 (39.4)  |
A univariate analysis of mortality risk factors is presented in the supplementary table (Table S2). In the multivariate regression model (Table 7), mortality was significantly higher in older patients (OR = 1.04, p = 0.007), and in patients admitted to a critical care unit (OR = 3.92, p = 0.004). Conversely, patients for whom the central venous catheter was removed following the diagnosis of fungemia were less likely to be dead at 30 days (OR = 0.189, p = 0.021). There was no significant difference in the mortality between NAC (57.5%) and C. albicans candidemia (51.7%, p = 0.473).

Table 7. Multivariate regression for predictors of 30-day mortality.

| Variable                          | OR (95% CI)    | p-Value |
|-----------------------------------|----------------|---------|
| Age                               | 1.04 (1.01–1.07)| 0.007   |
| Admission to critical care units  | 3.92 (1.54–9.94)| 0.004   |
| Central venous catheter removal   | 0.189 (0.046–0.779)| 0.021 |

Variables included in the model were: age; neutropenia; unknown source; echocardiography; ophthalmic exam; first antifungal anidulafungin; central venous catheter removed; critical care. OR: Odds Ratio.

3. Discussion

Although candidemia remains a cause of significant mortality and high economic burden worldwide, studies on candidemia in the Arab world remain limited, [8] with no data from Lebanon [11]. We report herein the first large series of candidemia at a tertiary hospital in Lebanon, detailing the characteristics, epidemiology, and outcomes of 170 candidemia episodes over a 16-year period.

Our study conforms with worldwide observations about the predominance of NAC [12], with 64.7% of the episodes caused by non-albicans species. Recent studies in the Arab countries were concordant with this global trend, reporting NAC rates of around 70% [8]. However, we found that C. glabrata is the most common causative agent for NAC in Lebanon (51.4% of speciated NAC). While this agrees with data from the United States, other regions such as Europe and Latin America have a much lower prevalence of C. glabrata [12]. This result also contrasts with data from neighboring countries in the Arab league, where C. tropicalis and C. parapsilosis were the most commonly reported causes of NAC, while C. glabrata represented only 0–19.2% of the cases [13–17]. C. glabrata is often associated with a higher mortality rate [18]. It is also inherently less susceptible to azole antifungals, with recent emergence of isolates resistant to echinocandins and amphotericin B [19,20], which highlights the importance of species identification and antifungal susceptibility testing in candidemia. Mixed candidemia was observed in four cases, and was associated with CLABSI three out of four times, a finding that was similarly reported in other studies [21]. Others have reported the effect of azole exposure on NAC emergence [22–24], which is consistent with our finding of antifungal use being associated with an almost threefold increase in the risk of developing NAC. We did not, however, find any association between NAC and other reported risk factors, such as immunosuppression, parenteral nutrition, old age, and critical illness [25]. An important finding in our study was that patients with CVC were less likely to develop NAC (OR = 0.48, p = 0.048), which contradicts other studies [26].

Although C. albicans is generally considered susceptible to fluconazole, reports of C. albicans’ sensitivity to fluconazole are widely variable in the literature (35–100%) [13,27,28]. Among the 24 C. albicans isolates in our cohort, 3 (12.5%) were resistant to fluconazole. None of these three patients had received antifungal therapy in the month preceding the candidemia, and all three had a solid malignancy and died within 30 days. An additional C. albicans isolate was also resistant to voriconazole. Among non-albicans isolates, P. kudriavzevii (C. krusei) displayed the highest resistance to fluconazole (60%), followed by C. glabrata (30.3%). C. tropicalis was resistant to fluconazole and to voriconazole in 7.1% and 8.3% of the tested isolates, respectively. This highlights the clinical significance of NAC, as these species have a widely reported resistance to azoles. Only 1 C. glabrata isolate was resistant to amphotericin B, and all tested isolates (14) were susceptible to caspofungin. In light of these results, the
practice of empiric therapy of candidemia with echinocandin followed by step-down therapy to fluconazole in susceptible isolates is justified by our results [29].

In our cohort, 30-day mortality was 55.5%, falling in the range of crude mortality reported elsewhere (40–60%) [3–5,8]. Risk factors associated with higher mortality are not uniform among studies, with some characteristics reported including intensive care unit stay, CLABSI, septic shock [30], advanced age [31], acute kidney injury, malignancy [8], and neutropenia [32]. While NAC is associated with increased mortality in some series [27], it is associated with decreased mortality in others [33]. There was no statistically significant difference in mortality between NAC and *Candida* albicans candidemia in our cohort (OR = 1.3, *p* = 0.473). However, older patients in our study and patients admitted to a critical care unit had a higher 30-day mortality.

Candidemia management guidelines are evolving, and some recommendations remain controversial [29,34]. In our center, echinocandins were the most common first-line antifungals used, which is consistent with the current guidelines [29]. Moreover, concerning the controversies over central venous catheter removal following the diagnosis of candidemia [34], we show in our cohort that this approach was associated with decreased mortality.

This study has a few limitations, including its retrospective nature. Medical records were not available for 23 candidemia cases identified in the Electronic Health Records. We also did not exclude terminal patients, in whom antifungal therapy was withheld due to patient/family wishes for a palliative care approach. Moreover, not all non-*albicans* isolates were speciated and tested for antifungal susceptibility, particularly among the isolates from the earlier years of the study.

4. Materials and Methods

We conducted a retrospective chart review at the American University of Beirut Medical Center (AUBMC), a tertiary care center in Lebanon, over a span of 16 years (2004–2019). AUBMC is the largest academic tertiary care center in Lebanon with a busy oncology unit including a stem cell transplant service, and medical and surgical intensive care units receiving patients from across Lebanon as well as referrals from neighboring countries. Using the Electronic Health Records at our institution, we identified all occurrences where *Candida* species grew in blood cultures. We included all episodes of candidemia occurring in patients ≥18 years old. Recurrence was considered when two episodes of candidemia occurred ≥7 days apart with clinical and microbiological resolution in the interim. We excluded cases where medical records were not available. We excluded from the mortality analysis cases where the outcome at 30 days was not available.

We reviewed the medical records of all cases and extracted data on demographics (age, sex), comorbid conditions (diabetes mellitus, hemodialysis), immunosuppression (malignancy, chemotherapy, or immunotherapy within the previous 30 days, hematopoietic or solid organ transplantation, neutropenia, steroid exposure, congenital, or acquired immunodeficiency syndromes), and patient characteristics at the onset of infection (hospital unit, mechanical ventilation, presence of CVC, parental nutrition, and abdominal surgery within the previous 30 days, antibiotic and antifungal history within the previous 30 days, source of candidemia). We defined neutropenia as an absolute neutrophil count (ANC) <1500 cells/mm$^3$ which we classified as mild (<1500 and ≥1000 cells/mm$^3$), moderate (<1000 and ≥500 cells/mm$^3$), or severe (<500 cells/mm$^3$) [35]. We defined steroid exposure as intake of the equivalent of 20 mg of prednisone for more than 1 month. We used the National Healthcare Safety Network definition of CLABSI [36]. We classified an episode as NAC whenever a non-*albicans* *Candida* species was recovered from the initial blood culture, whether it occurred alone or as a co-infection with *Candida albicans*.

Blood culture bottles were incubated in a BACT/ALERT® system (Durham, North Carolina, NC, USA), and *Candida* species identification and antifungal susceptibility testing were done using VITEK® 2 system (BioMérieux, Marcy L’Etoile, France). Antifungal susceptibility was reported using the Clinical and Laboratory Standards Institute criteria [37].
We analyzed data using IBM SPSS version 22 (IBM, New York, NY, USA). We described continuous data using mean and standard deviation, and we used the Student t-test for comparison between groups. For categorical data, we used the Pearson chi-square test or Fisher’s exact test for comparison. Multivariate regression was used to investigate risk factors for NAC and 30-day mortality using a stepwise approach. Risk factors with p-value < 0.05 in univariate analysis were included in the model. Predictors with p-values < 0.05 were considered as statistically significant.

5. Conclusions

Candidemia is associated with a high mortality in Lebanon, irrespective of the causative species. NAC is more common than *albicans* candidemia, with *C. glabrata* being the leading cause of non-*albicans* infections. These local epidemiological data are of paramount importance for the development of optimal treatment strategies and tackling current controversies in management.

Supplementary Materials: The following are available online at https://www.mdpi.com/2076-0817/10/1/82/s1, Table S1: Antifungal susceptibility of *Candida* isolates to amphotericin B and caspofungin, Table S2: Univariate analysis of possible risk factors associated with 30-day mortality.

Author Contributions: Conceptualization, S.S.K., A.E.Z., A.G. and M.A.; methodology, A.G. and M.A.; formal analysis, R.I. and H.T.; investigation, M.A., A.G., M.A.T. and J.-F.J.; resources, G.F.A.; writing—original draft preparation, R.I. and A.E.Z.; writing—review and editing, A.G., M.A., M.A.T., J.-F.J. and S.S.K.; visualization, A.E.Z.; supervision, S.S.K. and A.E.Z.; project administration, S.S.K. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Institutional Review Board of the American University of Beirut (protocol code BIO-2019-0290, approved in August 2019).

Informed Consent Statement: Patient consent was waived due to the retrospective nature of the study.

Data Availability Statement: The data presented in this study are available on request from the corresponding author. The data are not publicly available due to privacy.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Antinori, S.; Milazzo, L.; Sollima, S.; Galli, M.; Corbellino, M. Candidemia and Invasive Candidiasis in Adults: A Narrative Review. *Eur. J. Intern. Med.* 2016, 34, 21–28. [CrossRef] [PubMed]
2. Wan Ismail, W.N.A.; Jasmi, N.; Khan, T.M.; Hong, Y.H.; Neoh, C.F. The Economic Burden of Candidemia and Invasive Candidiasis: A Systematic Review. *Value Health Reg. Issues* 2020, 21, 53–58. [CrossRef]
3. Lortholary, O.; Renaudat, C.; Sitbon, K.; Madec, Y.; Denoeud-Ndam, L.; Wolff, M.; Fontanet, A.; Bretagne, S.; Dromer, F. Worrisome Trends in Incidence and Mortality of Candidemia in Intensive Care Units (Paris Area, 2002–2010). *Intensive Care Med.* 2014, 40, 1303–1312. [CrossRef] [PubMed]
4. Paiva, J.-A.; Pereira, J.M.; Tabah, A.; Mikstacki, A.; de Carvalho, F.B.; Koulenti, D.; Ruckly, S.; Çakar, N.; Misset, B.; Dimopoulos, G.; et al. Characteristics and Risk Factors for 28-Day Mortality of Hospital Acquired Fungemias in ICUs: Data from the EUROBACT Study. *Crit. Care* 2016, 20. [CrossRef] [PubMed]
5. Colombo, A.L.; Guimarães, T.; Sukienik, T.; Pasqualotto, A.C.; Andreotti, R.; Queiroz-Telles, F.; Nouër, S.A.; Nucci, M. Prognostic Factors and Historical Trends in the Epidemiology of Candidemia in Critically Ill Patients: An Analysis of Five Multicenter Studies Sequentially Conducted over a 9-Year Period. *Intensive Care Med.* 2014, 40, 1489–1498. [CrossRef] [PubMed]
6. Alves, J.; Palma, P.; Azevedo, D.; Rello, J. Candidemia in the Patient with Malignancy. *Hosp. Pract.* 2018, 46, 246–252. [CrossRef]
7. Giacobbe, D.R.; Maraolo, A.E.; Simeon, V.; Magnè, F.; Pace, M.C.; Gentile, I.; Chiodini, P.; Viscoli, C.; Sanguinetti, M.; Mikulska, M.; et al. Changes in the Relative Prevalence of Candidaemia Due to Non-*albicans* Candida Species in Adult in-Patients: A Systematic Review, Meta-Analysis and Meta-Regression. *Mycoses* 2020, 63, 334–342. [CrossRef]
8. Kmeid, J.; Jabbour, J.-F.; Kanj, S.S. Epidemiology and Burden of Invasive Fungal Infections in the Countries of the Arab League. *J. Infect. Public Health* 2019. [CrossRef]
9. Araj, G.F.; Daher, N.K.; Tabbarah, Z.A. Antifungal Susceptibility of Candida Isolates at the American University of Beirut Medical Center. Int. J. Antimicrob. Agents 1998, 10, 291–296. [CrossRef]

10. Araj, G.F.; Asmar, R.G.; Avedissian, A.Z. Candida Profiles and Antifungal Resistance Evolution over a Decade in Lebanon. J. Infect. Dev. Cities. 2015, 9, 997–1003. [CrossRef]

11. Ghazi, S.; Rafel, R.; Osman, M.; El Safadi, D.; Maliat, H.; Papon, N.; Dabboussi, F.; Cauahara, J.-P.; Hamze, M. The Epidemiology of Candida Species in the Middle East and North Africa. J. Med. Microbiol. 2019, 29, 245–252. [CrossRef] [PubMed]

12. Pfaller, M.A.; Diekema, D.J. Epidemiology of Invasive Candidiasis: A Persistent Public Health Problem. Clin. Microbiol. Rev. 2007, 20, 133–163. [CrossRef] [PubMed]

13. Al Thaqafi, A.H.O.; Farahat, F.M.; Al Harbi, M.I.; Al Amri, A.F.W.; Perfect, J.R. Predictors and Outcomes of Candida Bloodstream Infection: Eight-Year Surveillance, Western Saudi Arabia. Int. J. Infect. Dis. 2014, 21, 5–9. [CrossRef] [PubMed]

14. Mokaddas, E.M.; Al-Sweih, N.A.; Khan, Z.U. Species Distribution and Antifungal Susceptibility of Candida Bloodstream Isolates in Kuwait: A 10-Year Study. J. Med. Microbiol. 2007, 56, 255–259. [CrossRef] [PubMed]

15. Ellis, M.; Hedstrom, U.; Jumaa, P.; Bener, A. Epidemiology, Presentation, and Outcome of Candidemia in a Tertiary Care Teaching Hospital in the United Arab Emirates, 1995–2001. Med. Mycol. 2003, 41, 521–528. [CrossRef]

16. Arrache, D.; Madani, K.; Zait, H.; Achir, I.; Younis, N.; Zebdi, A.; Bouahri, L.; Chaouche, F.; Hamrioui, B. Fonction diagnostiques au laboratoire de parasitologie-mycologie du CHU Mustapha d’Alger, Algérie (2004–2014). J. Mycol. Méd. 2015, 25, 237–238. [CrossRef]

17. Sellami, A.; Sellami, H.; Néji, S.; Makni, F.; Abbes, S.; Cheikhrouhouf, F.; Chelly, H.; Bouaziz, M.; Hammami, B.; Ben Jemaa, M.; et al. Antifungal Susceptibility of Bloodstream Candida Isolates in Sfax Hospital: Tunisia. Mycopathologia 2011, 171, 417–422. [CrossRef]

18. Andes, D.R.; Safdar, N.; Baddley, J.W.; Alexander, B.; Brumble, L.; Freifeld, A.; Hadley, S.; Herwaldt, L.; Kaufman, C.; Lyon, G.M.; et al. The Epidemiology and Outcomes of Invasive Candida Infections among Organ Transplant Recipients in the United States: Results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Transpl. Infect. Dis. 2016, 18, 921–931. [CrossRef]

19. Dannaoui, E.; Desnos-Ollivier, M.; Garcia-Hermoso, D.; Grenouillet, F.; Cassaing, S.; Baixench, M.-T.; Bretagne, S.; Dromer, F.; Lortholary, O. Candida spp. with Acquired Echinocandin Resistance, France, 2004–2010. Emerg. Infect. Dis. 2012, 18, 86–90. [CrossRef]

20. Khan, Z.U.; Ahmad, S.; Al-Obaid, I.; Al-Sweih, N.A.; Joseph, L.; Farhat, D. Emergence of Resistance to Amphotericin B and Triazoles in Candida Glabrata Vaginal Isolates in a Case of Recurrent Vaginitis. J. Chemother. 2008, 20, 488–491. [CrossRef]

21. Ramos, A.; Romero, Y.; Sánchez-Romero, I.; Fortún, J.; Paño, J.R.; Pemán, J.; Gurguí, M.; Rodríguez-Baño, J.; Padilla, B. Risk Factors, Clinical Presentation and Prognotic of Mixed Candidaemia: A Population-Based Surveillance in Spain. Mycoses 2016, 59, 636–643. [CrossRef] [PubMed]

22. Chow, J.K.; Golan, Y.; Ruthazer, R.; Karchmer, A.W.; Carmeli, Y.; Lichtenberg, D.; Chawla, V.; Young, J.; Hadley, S. Factors Associated with Candidemia Caused by Non-albicans Candida Species versus Candida Albicans in the Intensive Care Unit. Clin. Infect. Dis. 2008, 46, 1206–1213. [CrossRef] [PubMed]

23. Playford, E.G.; Marriott, D.; Nguyen, Q.; Chen, S.; Ellis, D.; Slavin, M.; Sorrell, T.C. Candidemia in Nonneutropenic Critically Ill Patients: Risk Factors for Non-albicans Candida spp. Crit. Care Med. 2008, 36, 2034–2039. [CrossRef] [PubMed]

24. Kofteridis, D.P.; Valachis, A.; Dimopoulou, D.; Andrianaki, A.M.; Christidou, A.; Maraki, S.; Vazquez, J.; Gurt, A.; et al. Pathogens 2021, 32. Uzun, O.; Anaissie, E.J. Predictors of Outcome in Cancer Patients with Candidemia. Ann. Oncol. 2000, 11, 1517–1521. [CrossRef] [PubMed]

25. Al-Tawfiq, J.A. Distribution and Epidemiology of Candida Species Causing Fungemia at a Saudi Arabian Hospital, 1996–2004. Int. J. Infect. Dis. 2007, 11, 239–244. [CrossRef] [PubMed]
34. El Zakhem, A.; Saad, H.; Tayyar, R.; Kanj, S.S. Controversies in Candida Management. *Int. J. Antimicrob. Agents* 2015, 46 (Suppl. S1), S43–S46. [CrossRef]

35. Boxer, L.A. How to Approach Neutropenia. *Hematol. Am. Soc. Hematol. Educ. Program* 2012, 2012, 174–182. [CrossRef]

36. Bloodstream Infections; National Healthcare Safety Network, 2021; p. 4. Available online: https://www.cdc.gov/nhsn/pdfs/pscmanual/4psc_clabscurrent.pdf (accessed on 18 January 2021).

37. Alexander, B.D. Clinical and Laboratory Standards Institute. In *Performance Standards for Antifungal Susceptibility Testing of Yeasts*; 2017; ISBN 978-1-56238-828-7. Available online: https://clsi.org/media/1895/m60ed1_sample.pdf (accessed on 18 January 2021).